

# Contribution of Stress Responses to Antibiotic Tolerance in *Pseudomonas aeruginosa* Biofilms

Philip S. Stewart,<sup>a</sup> Michael J. Franklin,<sup>b</sup> Kerry S. Williamson,<sup>b</sup> James P. Folsom,<sup>a\*</sup> Laura Boegli,<sup>a</sup> Garth A. James<sup>a</sup>

Department of Chemical and Biological Engineering and Center for Biofilm Engineering, Montana State University, Bozeman, Montana, USA<sup>a</sup>; Department of Microbiology and Center for Biofilm Engineering, Montana State University, Bozeman, Montana, USA<sup>b</sup>

**Enhanced tolerance of biofilm-associated bacteria to antibiotic treatments is likely due to a combination of factors, including changes in cell physiology as bacteria adapt to biofilm growth and the inherent physiological heterogeneity of biofilm bacteria. In this study, a transcriptomics approach was used to identify genes differentially expressed during biofilm growth of *Pseudomonas aeruginosa*. These genes were tested for statistically significant overlap, with independently compiled gene lists corresponding to stress responses and other putative antibiotic-protective mechanisms. Among the gene groups tested were those associated with biofilm response to tobramycin or ciprofloxacin, drug efflux pumps, acyl homoserine lactone quorum sensing, osmotic shock, heat shock, hypoxia stress, and stationary-phase growth. Regulons associated with Anr-mediated hypoxia stress, RpoS-regulated stationary-phase growth, and osmotic stress were significantly enriched in the set of genes induced in the biofilm. Mutant strains deficient in *rpoS*, *relA* and *spoT*, or *anr* were cultured in biofilms and challenged with ciprofloxacin and tobramycin. When challenged with ciprofloxacin, the mutant strain biofilms had 2.4- to 2.9-log reductions in viable cells compared to a 0.9-log reduction of the wild-type strain. Interestingly, none of the mutants exhibited a statistically significant alteration in tobramycin susceptibility compared to that with the wild-type biofilm. These results are consistent with a model in which multiple genes controlled by overlapping starvation or stress responses contribute to the protection of a *P. aeruginosa* biofilm from ciprofloxacin. A distinct and as yet undiscovered mechanism protects the biofilm bacteria from tobramycin.**

The enhanced antibiotic tolerance of microorganisms growing in biofilms has been recognized for decades (1) yet remains an unsolved problem. The problem is unsolved both at the level of a fundamental understanding of the tolerance mechanisms and at the development of improved therapies for biofilm infections. These two aspects are interrelated. Insight into the mechanisms of biofilm antibiotic tolerance might lead to the identification of new targets for curing persistent biofilm infections. Therapies that work *in vivo* would provide clues about the mechanisms of biofilm antibiotic tolerance. Several studies have reported on the increased tolerance of *Pseudomonas aeruginosa* growing in biofilms compared to that of the same strain growing planktonically (2–4). Published data on biofilm and planktonic susceptibility of *P. aeruginosa* to ciprofloxacin and tobramycin, which is also the model system examined in this work, are summarized in Table 1. These comparisons consistently demonstrate enhanced tolerance of biofilm cells to these two drugs. We note that the results of Folsom et al. (2), who used an experimental system identical to that reported in this article, establish the suitability of the drip-flow biofilm model as a basis for investigating biofilm antibiotic tolerance. When biofilms grown in this model were mechanically dispersed into a suspension and then treated with antibiotic, susceptibility was fully restored (2). This result confirmed that the reduced susceptibility of these biofilm cells was not due to the accumulation of antibiotic-resistant mutants in the biofilm.

Most antibiotics penetrate biofilms, suggesting that diffusion of the antibiotics into the biofilm is not the major source of biofilm tolerance (5, 6). Direct measurement of the delivery of fluoroquinolone antibiotics, such as ciprofloxacin, has consistently demonstrated the ready access of these agents to the biofilm bacteria (7–11). In comparison, aminoglycoside antibiotics have slower biofilm penetration (10, 11). The retarded delivery of these drugs is hypothesized to derive from binding of the cationic ami-

noglycoside to negatively charged polymers in the biofilm matrix. Sorption, however, is not a mechanism of exclusion. Over longer exposure times comparable to those realized *in vivo*, even aminoglycosides are expected to penetrate biofilm cells (5, 10).

Biofilm tolerance is not primarily an issue of resistance mechanisms, such as the acquisition of a mutation or mobile genetic element that confers heritable protection (12). A common feature of biofilm tolerance is that antibiotic susceptibility can be restored by physically dispersing microbial cells from the biofilm and growing them in planktonic mode. This suggests that biofilm tolerance to antibiotics is associated with a reversible phenotypically derived state. Heritable resistance mechanisms may arise in biofilms over the long term (13, 14), just as they do in planktonic cultures.

A number of gene products with enzymatic or structural properties, including PA0084 (*tssC1*) (15), PA1163 (*ndvB*) (16), PA1875 to PA1877 (17), and PA3063 (*pelB*) (18), have been reported to modulate *P. aeruginosa* biofilm susceptibility to antibiotics. However, if multiple functions are required for biofilm

Received 19 February 2015 Returned for modification 14 March 2015

Accepted 7 April 2015

Accepted manuscript posted online 13 April 2015

Citation Stewart PS, Franklin MJ, Williamson KS, Folsom JP, Boegli L, James GA. 2015. Contribution of stress responses to antibiotic tolerance in *Pseudomonas aeruginosa* biofilms. *Antimicrob Agents Chemother* 59:3838–3847. doi:10.1128/AAC.00433-15.

Address correspondence to Philip S. Stewart, phil\_s@biofilm.montana.edu.

\* Present address: James P. Folsom, Chatsworth, Georgia, USA.

Supplemental material for this article may be found at <http://dx.doi.org/10.1128/AAC.00433-15>.

Copyright © 2015, American Society for Microbiology. All Rights Reserved.

doi:10.1128/AAC.00433-15

TABLE 1 Antibiotic tolerance of biofilms of *P. aeruginosa* strain PAO1

Model system	Agent <sup>a</sup>	Log reduction in:			Reference
		Biofilm cells	Planktonic cells	Tolerance factor <sup>b</sup>	
Drip-flow	TOB	0.72	3.18	4.4	2
Drip-flow	CIP	1.37	4.84	3.5	2
Colony biofilm	TOB	0.52	5.67	10.9	3
Colony biofilm	CIP	1.13	5.05	4.5	3
Silicone tube	TOB	0.35	3.20	9.1	4

<sup>a</sup> TOB, tobramycin; CIP, ciprofloxacin.

<sup>b</sup> The tolerance factor is the log reduction in viable counts for planktonic cells divided by the log reduction in viable counts for biofilm cells.

antibiotic tolerance or if there is redundancy in protective gene functions, a single mutation may show little detectable phenotypic difference in biofilm antibiotic tolerance. It is likely that the genetic basis of biofilm protection from antibiotics derives from multiple overlapping responses involving dozens of different genes. Several regulators of multiple genes have been shown to affect *P. aeruginosa* antibiotic tolerance, including PA0934 and PA5338 (*relA* and *spoT*) (19), PA4878 (*brlR*) (4, 20), and PA5332 (*crc*) (21).

The focus of antibiotic tolerance thus shifts to an understanding of the physiology of the cells within a biofilm, which are inherently heterogeneous. Individual biofilms may contain subpopulations of actively growing cells, nongrowing cells (10, 22–27), bacteria undergoing stress responses (19, 28–35), and cells in a persister state (36, 37). Since differential gene expression precedes entry of the cells into each of these physiological states, we predict that as biofilm cells enter protected phenotypic states, a subset of the differentially expressed genes will contribute to antibiotic tolerance. Therefore, the goal of this research was to identify classes of genes that are differentially expressed in *P. aeruginosa* biofilms during the biofilm antibiotic-tolerant state and to determine if induction of those groups of genes plays a role in the protection of *P. aeruginosa* from antibiotic treatments.

## MATERIALS AND METHODS

**Bacterial strains, growth conditions, and antibiotics.** *P. aeruginosa* strain PAO1 and its mutant derivatives (Table 2) were cultured in *Pseudomonas* basal mineral medium (PBM) (38) containing 0.2 g liter<sup>-1</sup> glucose for experiments measuring growth or antibiotic susceptibility. Inocula were grown in the same medium containing 1 g liter<sup>-1</sup> glucose. Mutant strains with transposon insertions in *anr*, *rpoS*, *mvfR*, and *brlR* were obtained from the University of Washington *Pseudomonas aeruginosa* two-allele library (39). The *P. aeruginosa*  $\Delta$ *relA*  $\Delta$ *spoT* mutant was graciously provided by Pradeep Singh (19), and the *P. aeruginosa*  $\Delta$ *lasI*  $\Delta$ *rhlI* mutant was graciously provided by Herb Schweizer (40). Cultures were prepared in shake flasks at 37°C with agitation at 200 rpm. Tobramycin sulfate and ciprofloxacin hydrochloride were obtained from Sigma-Aldrich. Viable cell numbers were determined as CFU on tryptic soy agar (TSA) (Becton Dickinson).

**Drip-flow biofilm growth.** Biofilms were formed in the continuous flow drip-flow biofilm reactor (41) using PBM supplemented with 0.2 g liter<sup>-1</sup> glucose. This reactor contained four parallel chambers that were covered with polycarbonate lids containing septa for the introduction of medium using 22-gauge needles and a filtered air vent. Medium was pumped into the chambers at a flow rate of 60 ml h<sup>-1</sup>, dripping onto the stainless steel slides (8.5 cm by 1.3 cm) placed in the chambers. The reactors were placed on a stand inclined at 10° from horizontal, and PBM flowed along the length of the coupon and drained from the reactor. The

TABLE 2 Bacterial strains

Strain	Relevant characteristics	Source
PAO1	Wild type	MJF archive
PW3784	<i>anr</i> -E05::ISlacZ/hah	39
PW7151	<i>rpoS</i> -B03::ISlacZ/hah $\Delta$ <i>relA</i> $\Delta$ <i>spoT</i>	39 19
PW2812	<i>mvfR</i> -G11::ISlacZ/hah	39
PW9205	<i>brlR</i> -C05::ISlacZ/hah	39
PAO216	$\Delta$ <i>lasI</i> $\Delta$ <i>rhlI</i>	40

reactors were inoculated by adding 1 ml of an overnight culture to 15 ml of fresh PBM to cover the slides (inoculum optical density at 600 nm [OD<sub>600</sub>], ≈0.3) in PBM (1 g liter<sup>-1</sup> glucose). The reactor was sealed by clamping the effluent tubes, and the inoculum was allowed to incubate in the reactor for 18 to 24 h on a level surface. After the inoculation period, the reactor was inclined, and the medium flow was initiated. The entire drip-flow reactor system was maintained at 37°C. The biofilms were cultured in the drip-flow reactors for 72 h after the static inoculation phase.

**Antibiotic susceptibility of biofilms.** After 72 h of growth in the absence of antibiotic, antibiotics were added to the growth medium, and the flow with the medium containing antibiotic was continued for an additional 12 h. Tobramycin was applied at 10 μg ml<sup>-1</sup> and ciprofloxacin at 1.0 μg ml<sup>-1</sup>. After treatment, the stainless steel coupons were removed from the reactor, and the number of viable cells was determined by scraping the biofilms into 10 ml of phosphate-buffered saline and then vortexing, sonicating, and vortexing again to disperse cell aggregates. The resulting cell suspensions were serially diluted and plated on TSA. Killing was reported in log reductions. The log reduction was calculated relative to the cell count at the onset of treatment. The experiments were performed at least in triplicate.

**Preparation of biofilms and planktonic cultures for microarrays.** Biofilms were grown in the drip-flow reactor for 72 h and then treated with either tobramycin (*n* = 3) or ciprofloxacin (*n* = 3) for 12 h, as detailed above. Immediately after treatment, biofilms were scraped directly into 1 ml of RNAlater (Ambion). Clumps were dispersed by repeated pipetting with a micropipette, and the recovered biofilms were stored at 4°C for 1 day prior to removal of the RNAlater by centrifugation (15 min, 4°C, and 14,000 × *g*) and freezing of the biofilm cells at -70°C.

The antibiotic-treated biofilm cells were thawed on ice, resuspended in 300 μl of 1 mg lysozyme ml<sup>-1</sup> and Tris-EDTA (TE) buffer (10 mM Tris, 1 mM EDTA [pH 8.0]), and divided into three aliquots. Each aliquot was sonicated for 15 s, incubated at room temperature for 15 min, and then combined for application onto one extraction column. RNA was extracted with an RNeasy minikit (Qiagen Sciences) with on-column DNA digestion. RNA concentrations and purity were determined using a NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies). RNA quality was evaluated using the RNA 6000 NanoChip assay on a 2100 Bioanalyzer (Agilent Technologies).

Four *P. aeruginosa* planktonic cultures were grown from frozen stocks in *Pseudomonas* basal medium containing 1.0 g liter<sup>-1</sup> glucose overnight. Thirty microliters of each of these cultures was used to inoculate 30 ml of PBM (1 g liter<sup>-1</sup> glucose). The cultures were allowed to incubate at 37°C with orbital shaking at 200 rpm for 5 h. Exponential-phase cells (OD<sub>600</sub> ≈0.26) were collected by centrifugation at 11,000 × *g* and 4°C for 3 min. The supernatant was carefully removed, and 1 ml of RNAlater (Ambion) was added to the cell pellet and mixed thoroughly by a pipette. RNA extraction was then performed as described for the biofilm samples, except that samples were not divided or sonicated. Four planktonic biological replicates were processed independently.

**Microarray hybridization.** Isolated total RNA (10 μg for antibiotic-treated biofilms and 8 μg for planktonic cultures) was reverse transcribed, fragmented using DNase I, and biotin end labeled according to the Affymetrix prokaryotic target labeling protocol (GeneChip expression anal-

ysis technical manual, November 2004). For each *Pseudomonas* genome array (catalog no. 900339; Affymetrix), labeled fragmented cDNA (4.5 µg from antibiotic-treated biofilms or 3 µg from planktonic cultures) was hybridized to the arrays at 50°C for 16 h with constant rotational mixing at 60 rpm. Washing and staining of the arrays were performed using the Affymetrix GeneChip fluidics station 450. The arrays were scanned using an Affymetrix GeneChip scanner 7G and GCOS software version 1.4.

**Analysis of biofilm and planktonic microarray data.** The Affymetrix .CEL files were imported into FlexArray version 1.6.1 for quality control, normalization, and data analysis (M. Blazejczyk, M. Miron, R. Nadon, Génome Québec, Montreal, Canada) Previously published data from untreated biofilms grown in the drip-flow reactor for either 72 h ( $n = 3$ ) or 84 h ( $n = 3$ ) were imported into FlexArray and pooled. Microarray data were background corrected and normalized using the GeneChip robust multiarray averages (GC-RMA) algorithm. Gene expression in untreated biofilms and planktonic cells was compared with an analysis of variance (ANOVA) and false-discovery rate (FDR) correction using the Benjamini Hochberg algorithm to generate a list of genes with expression changes of >4-fold at an adjusted  $P$  value of  $\leq 0.01$  (see Table S1 in the supplemental material). A similar analysis was performed to identify changes in gene expression between untreated biofilms and antibiotic-treated biofilms of >4-fold at a  $P$  value of  $\leq 0.01$  (see Table S2 in the supplemental material).

To identify the physiological activities represented by the gene lists, the lists were compared to lists of genes associated with particular responses or activities, such as iron limitation, quorum sensing, or nitrosative stress. These activity gene lists were compiled from the literature, as documented in Table S3 in the supplemental material.  $P$  values for assessing the statistical significance of gene set enrichment were calculated using a negative binomial distribution. The gene lists were also uploaded into the Database for Annotation, Visualization and Integrated Discovery (DAVID) for the identification of enriched biological themes with the functional annotation clustering tool (43, 44).

**Microarray data accession no.** The data discussed in this publication have been deposited in the NCBI Gene Expression Omnibus (42) and are accessible through GEO series accession no. GSE65882.

## RESULTS AND DISCUSSION

**Anabolic and catabolic pathways are downexpressed in *P. aeruginosa* biofilms.** Microarray-based transcriptional profiling was used to develop insight into the physiological activities of biofilm bacteria. Based on a 4-fold difference in transcript abundance and an adjusted  $P$  value of  $\leq 0.01$ , *P. aeruginosa* had 340 genes with increased expression in 3-day drip-flow biofilms, compared to exponential-phase planktonic cells, and 683 genes with reduced expression in the biofilms (see Table S1 in the supplemental material).

We used DAVID analysis (43, 44) to identify the metabolic pathways associated with these differentially expressed genes (Table 3). Clusters of genes that were significantly enriched in the list of genes with increased expression in biofilm samples included genes for nitrogenous compound oxidoreductase activity, heme or heme-copper binding, and organic acid catabolic processes (Table 3). The first two of these groups are likely associated with anaerobic and microaerophilic respiration, respectively. Numerous pathways were significantly reduced in expression in the biofilm samples. Catabolic pathways, including genes for the tricarboxylic acid (TCA) cycle, NADH dehydrogenase activity, and cellular respiration, were downexpressed in biofilms. Transcription was also reduced for many anabolic pathways, including amino acid and nucleotide biosynthesis, translation, lipid biosynthesis, and DNA metabolism. The downexpressed pathways were not surprising based on our previous studies of heterogeneity in biofilms (26, 45). In those studies, we demonstrated that in thick *P. aeruginosa* biofilms, the lower portion of the biofilm had tran-

TABLE 3 Gene enrichment analysis of *P. aeruginosa* biofilms compared to planktonic cells based on Gene Ontology groups (43, 44)

Gene Ontology term	Gene count	$P$ value
Upexpressed in biofilms		
Nitrogenous compound/oxidoreductase activity	8	$2.3 \times 10^{-10}$
Heme binding	16	$1.2 \times 10^{-8}$
Heme-copper terminal oxidase activity	5	$1.8 \times 10^{-3}$
Organic acid catabolic processes	6	$3.2 \times 10^{-3}$
Downexpressed in biofilms		
Nitrogen compound biosynthetic processes	107	$9.0 \times 10^{-29}$
Translation	71	$1.3 \times 10^{-42}$
tRNA aminoacylation	20	$3.0 \times 10^{-12}$
Nucleotide biosynthesis	39	$7.7 \times 10^{-16}$
Tricarboxylic acid cycle	12	$5.8 \times 10^{-6}$
Histidine biosynthesis	11	$1.2 \times 10^{-7}$
NADH dehydrogenase activity	12	$3.4 \times 10^{-8}$
GTP binding	15	$3.6 \times 10^{-6}$
RNA processing	24	$3.5 \times 10^{-4}$
Lipid biosynthetic processes	37	$1.6 \times 10^{-9}$
Aspartate family amino acid biosynthesis	14	$4.8 \times 10^{-6}$
Glutamine family amino acid biosynthesis	18	$2.2 \times 10^{-4}$
Nucleotide kinase activity	5	$2.0 \times 10^{-4}$
DNA topoisomerase activity	5	$7.1 \times 10^{-5}$
Glycolysis	10	$5.0 \times 10^{-5}$
Coenzyme/folic acid metabolic processes	33	$2.8 \times 10^{-7}$
Metal ion binding	99	$7.6 \times 10^{-4}$
Alcohol biosynthetic processes	7	$1.2 \times 10^{-4}$
Purine biosynthetic processes	23	$2.1 \times 10^{-9}$
Protein folding	11	$3.3 \times 10^{-3}$
Aromatic amino acid biosynthesis	16	$9.9 \times 10^{-4}$
Fatty acid biosynthesis	11	$3.3 \times 10^{-3}$
Cellular respiration	20	$7.2 \times 10^{-5}$
Pyrimidine biosynthetic processes	9	$4.4 \times 10^{-5}$
Nucleoside metabolic processes	14	$5.4 \times 10^{-4}$
DNA replication	1	$5.7 \times 10^{-3}$
Protein transmembrane transport	5	$2.3 \times 10^{-3}$

sitioned into an oxygen-starved low metabolic state, while the upper portion of the biofilm was in a transition state to stationary-phase growth. This would result in reduced overall anabolic and catabolic activities for the entire biofilm. Since the analysis here was performed on whole biofilms, the average expression of the catabolic and anabolic pathways showed reduced expression compared to that of exponential-phase planktonic cells.

**Gene sets associated with drug efflux, oxidative stress, SOS response, and heat shock do not overlap genes upexpressed in *P. aeruginosa* biofilms.** We hypothesized that some of the differentially expressed genes identified above contribute to the protection of biofilm from antibiotics. We also expected that many of those genes do not make a difference for the antibiotic tolerance of the biofilm. The challenge was to find an unbiased approach to analyze the data without focusing on a few known genes and neglecting poorly characterized genes. The Gene Ontology results in Table 3 focus primarily on catabolic or biosynthetic pathways. Since the exposure of bacteria to antibiotics likely induces stress responses in the bacteria, other specialized pathways, such as those involved in stress response or antibiotic resistance, may be induced. These pathways may not cluster with the pathways represented in the DAVID analysis. Therefore, to identify particular

**TABLE 4** Gene set enrichment analysis of hypothesized protective mechanisms and other stress responses in drip-flow reactor *P. aeruginosa* biofilms

Mechanism <sup>a</sup>	<i>P</i> value for overlap with genes		Reference(s)
	Up in biofilm	Down in biofilm	
Efflux pumps	0.916	0.994	53
Peroxide stress	0.071	1.000	48–51
SOS response	1.000	0.861	52
Heat shock and chaperones	0.852	0.012	53
Fe limitation	0.896	0.997	55, 55
Cyclic-di-GMP	0.910	0.957	56
Toxin-antitoxin modules	1.000	1.000	57
Planktonic sensitivity to CIP	0.364	0.256	58
Planktonic tolerance to CIP	0.965	0.020	59
Planktonic sensitivity to TOB	1.000	0.017	59
Response to TOB in DFB, up	0.993	$1.63 \times 10^{-8}$	Table S2
Response to TOB in DFB, down	$<1 \times 10^{-14}$	0.994	Table S2
Response to CIP in DFB, up	0.993	0.051	Table S2
Response to CIP in DFB, down	$1.50 \times 10^{-9}$	0.861	Table S2
Oxygen limitation	$<1 \times 10^{-14}$	1.000	62
Oxygen downshift	$<1 \times 10^{-14}$	1.000	63
Stationary phase	$<1 \times 10^{-14}$	1.000	62, 96–98
HSL quorum sensing	0.004	1.000	69–71
Osmotic stress	$1.11 \times 10^{-4}$	1.000	72

<sup>a</sup> CIP, ciprofloxacin; TOB, tobramycin; DFB, drip-flow biofilm; HSL, homoserine lactone.

subsets of genes that might be important for *P. aeruginosa* biofilm antibiotic tolerance, we compiled from the literature lists of genes associated with particular hypothesized antibiotic-protective mechanisms (see Table S3 in the supplemental material). We then compared those lists of genes to differentially expressed genes in the biofilm cells to determine if groups of genes associated with a particular stress response or environmental condition were statistically significantly enriched in the biofilm transcriptomes.

For example, one explanation for biofilm antibiotic tolerance is that drug efflux pumps are expressed at elevated levels in the biofilm, even prior to antibiotic treatment. We examined the overlap between a list of 39 genes associated with drug efflux in *P. aeruginosa* and the 340 genes expressed at higher levels in biofilm (Table 4). Only a single gene was common to both lists (PA4206, *mexH*), and this degree of overlap between the efflux pumps and genes upexpressed during biofilm growth was not statistically significant. This suggests that increased expression of multiple drug efflux pumps is likely not responsible for the antibiotic tolerances of these biofilm bacteria.

Oxidative stress has been shown to play a role in antibiotic sensitivity both in planktonic (32, 33) and biofilm cells (19), although the generality of this relationship has recently been questioned (46, 47). To test for an oxidative stress response in the biofilm, we compared the genes reported to be induced by hydrogen peroxide exposure in *P. aeruginosa* (48–51) with the genes upexpressed in the biofilm. The overlap was borderline significant ( $P = 0.07$ ; Table 4).

We tested for the involvement of other putative protective mechanisms in drip-flow biofilms. In the absence of antibiotics, there was no evidence of expression of the classes of genes associated with the SOS response (52), heat shock (53), iron limitation (54, 55), or cyclic-di-GMP metabolism (56) in these biofilms (Table 4).

Toxin-antitoxin modules have been associated with the formation of antibiotic-tolerant persister cells in biofilms (35, 37). In the *P. aeruginosa* PAO1 genome, several putative toxin-antitoxin modules have been identified by bioinformatic analysis (57). The predicted toxin-antitoxin genes were not among those differentially expressed in the drip-flow reactor biofilms (Table 4). This is not surprising, since our analyses were performed on whole biofilms, whereas the putative persister cells would only make up a small portion of the population. Therefore, the enhanced expression of these genes is not likely to be identified by this global analysis of whole biofilms.

Global screens of the transposon mutant libraries for *P. aeruginosa* mutants altered in their susceptibility to tobramycin or ciprofloxacin have been reported (58, 59). Those studies were done exclusively with planktonic bacteria. Nevertheless, it is plausible that a gene that modulates the antibiotic sensitivity of a planktonic cell might also modulate antibiotic susceptibility in a biofilm. In particular, a gene that when mutated renders a cell more sensitive to an antibiotic would be a candidate for a protective gene if it were constitutively upexpressed in the biofilm. No evidence for this general mechanism was found (Table 4). Another version of this hypothesis posits downregulation in the biofilm of a gene whose inactivation renders a cell more tolerant to the drug. A borderline-positive result (two genes,  $P = 0.02$ ) was found for ciprofloxacin (Table 4).

A number of gene products (with corresponding gene in parentheses) have been reported to modulate *P. aeruginosa* biofilm susceptibility to antibiotics: PA0084 (*tssC1*) (15), PA0934 and PA5338 (*relA spoT*) (19), PA1163 (*ndvB*) (16), PA1875 to PA1877 (17), PA3063 (*pelB*) (18), PA4878 (*brlR*) (4, 20), and PA5332 (*crc*) (21). None of these genes appear on our list of 340 upexpressed genes, and just one (*spoT*) appears on our list of 680 downexpressed drip-flow biofilm genes.

**Genes induced by treatment with tobramycin or ciprofloxacin do not overlap genes upexpressed in *P. aeruginosa* biofilms.** Biofilm bacteria may evade killing by antibiotics by deploying adaptive responses. For example, *P. aeruginosa* cells in the outer region of a biofilm have been shown to actively respond to treatment with colistin by expressing specific genes that protect these cells from the antimicrobial (34). Therefore, we also characterized the transcriptomic response of 3-day-old drip-flow reactor biofilms of *P. aeruginosa* treated with either tobramycin or ciprofloxacin. The microarray results of the biofilm cells that survived treatments with antibiotics indicated that 78 genes had increased expression, and 15 genes had reduced expression (4-fold increase, adjusted  $P < 0.01$ ) following 12 h of treatment with ciprofloxacin (see Table S2 in the supplemental material). Treatment with tobramycin resulted in the increased expression of 111 genes and decreased expression of 70 genes (4-fold increase,  $P \leq 0.01$ ) (see Table S2).

A DAVID analysis identified the pathways induced in biofilm cells by antibiotic exposure (Table 5). Ciprofloxacin induced genes for the SOS response, non-membrane-bound organelles, including *dnaT*, *rimM*, and *recN*, and genes for cytolysis, including genes for bacteriocin biosynthesis. Also induced by ciprofloxacin was the large prophage gene product cluster from PA0612 to PA0648. The gene pathways upexpressed by tobramycin included those for genes for ribosome biosynthesis and RNA metabolism, while the downexpressed genes included those for energy production, such as those for glycolysis, TCA cycle, and oxidative phosphorylation (Table 5).

**TABLE 5** Gene enrichment analysis of *P. aeruginosa* biofilms treated with antibiotics compared to untreated biofilms based on Gene Ontology groups

Gene Ontology term	Gene count	<i>P</i> value
Upexpressed in biofilms by ciprofloxacin		
Non-membrane-bound organelle	5	$8.3 \times 10^{-5}$
Cytolysis	3	$1.9 \times 10^{-3}$
SOS response	3	$8.0 \times 10^{-4}$
Downexpressed in biofilms by ciprofloxacin		
Arginine metabolic process	3	$3.1 \times 10^{-5}$
Heme binding	4	$1.2 \times 10^{-3}$
Upexpressed in biofilms by tobramycin		
Ribosome	12	$3.2 \times 10^{-13}$
RNA binding	11	$2.8 \times 10^{-7}$
RNA processing	9	$7.1 \times 10^{-5}$
SOS response	3	$4.2 \times 10^{-3}$
Downexpressed in biofilms by tobramycin		
Generation of precursor metabolites for energy	12	$5.8 \times 10^{-10}$
TCA cycle	5	$7.8 \times 10^{-5}$
Glycolysis/gluconeogenesis	5	$1.7 \times 10^{-4}$
Cellular respiration	5	$8.9 \times 10^{-4}$
Arginine metabolic process	3	$8.0 \times 10^{-3}$

One possible mechanism of biofilm protection from an antibiotic is that the genes that do provide adaptive protection are constitutively expressed in the biofilm state, even prior to antibiotic exposure. We tested for this possibility by comparing the genes induced in biofilms by tobramycin or ciprofloxacin with those upexpressed prior to antibiotic exposure and found no support for this hypothesis (Table 4). To the contrary, we found a statistically significant overlap between the genes expressed at higher levels in biofilm and the genes repressed in response to treatment with either antibiotic (Table 4).

Another interesting conjecture is that biofilms, in response to antibiotic treatment, express a set of genes that is distinct from the genes that are induced in antibiotic-exposed planktonic cells. Twenty-one genes were induced in drip-flow biofilms by both ciprofloxacin and tobramycin. Of these 21 genes, 16 have been reported to be induced by either ciprofloxacin or tobramycin (60, 61). This suggests that the transcriptional response of *P. aeruginosa* to ciprofloxacin and tobramycin is similar for cells growing planktonically and for biofilm cells.

**Genes associated with the responses to hypoxia, osmotic stress, growth arrest, and quorum sensing overlap genes up-expressed in *P. aeruginosa* biofilms.** Alvarez-Ortega and Harwood (62) characterized the transcriptional response of planktonic *P. aeruginosa* to oxygen limitation. A list compiled from their work of 159 genes expressed at elevated levels under some low-oxygen condition (in comparison to an air-saturated culture) overlaps extensively with the 340 genes expressed in our drip-flow biofilms (Table 4). These two lists have 58 genes in common, and the enrichment is highly statistically significant ( $P < 10^{-14}$ ). Similarly, from a list of 117 genes induced by a shift from aerobic to anaerobic conditions (63), 51 genes overlap this biofilm list ( $P < 10^{-14}$ ). These two comparisons show that bacteria in a biofilm experience hypoxia. These results on whole biofilms confirm our

**TABLE 6** Gene set enrichment analysis of regulatory gene activity in the 340 genes upexpressed in drip-flow reactor *P. aeruginosa* biofilms

Gene set <sup>a</sup>	Total no.	Overlap	<i>P</i>
MvfR <sup>+</sup>	115	34	$10^{-15}$
MvfR <sup>-</sup>	18	3	0.094
RpoS <sup>+</sup>	423	88	$10^{-15}$
RpoS <sup>-</sup>	176	14	0.189
Anr <sup>+</sup>	191	40	$10^{-12}$
Crc <sup>+</sup>	19	0	1.00
Crc <sup>-</sup>	47	5	0.158

<sup>a</sup> +, genes positively regulated by the indicated protein; -, genes negatively regulated by the indicated protein.

prior studies on localized gene expression in biofilms, which showed that cells at the top of colony biofilms were likely in a transition phase to hypoxia-induced stress, whereas cells at the bottom of biofilms had likely transitioned to anaerobic conditions (26). Microelectrode profiling of the oxygen concentrations of similar biofilms also showed that the concentration of oxygen rapidly decreased within about 50  $\mu\text{m}$  from the top of the biofilms (10, 23, 64).

We also found a statistically significant enrichment of genes associated with the stationary phase (see Table S3 in the supplemental material,  $P < 10^{-14}$ ), which again was similar to the top of the biofilms from our previous study. Acyl homoserine lactone quorum sensing has been shown to be important for *P. aeruginosa* biofilm formation (65–67) and to contribute to biofilm tolerance to tobramycin (68). We compiled a consensus list of quorum-sensing-activated genes from three independent studies (69–71; see also Table S3) and compared this list to genes expressed in *P. aeruginosa* drip-flow reactor biofilms. The enrichment of quorum-sensing-regulated genes was statistically significant in these biofilms ( $P = 4 \times 10^{-3}$ ) (Table 4).

Genes associated with osmotic stress (72) ( $P = 1 \times 10^{-4}$ ) were also significantly enriched in expression from the 340 genes up-expressed in biofilm growth (Table 4).

In summary, global gene expression patterns provide evidence of the following physiological activities or conditions in 3-day-old drip-flow biofilms: oxygen limitation, stationary-phase growth state, osmotic stress, and quorum sensing.

**Global gene expression patterns are consistent with activation of the RpoS, MvfR, and Anr regulons but not the Crc regulon.** To gain insight into the role of specific regulatory mechanisms in determining the gene expression in these biofilms, we compared lists of genes up- or downregulated by selected regulatory genes to those upexpressed in the biofilm transcriptome (Table 6). Both the hypoxia-responsive Anr regulon (63) and genes positively regulated by the stationary-phase sigma factor RpoS (73) were significantly enriched in the 340 genes upexpressed in biofilms (Table 6). Given the stationary-phase character of the biofilm, the stringent response is another likely regulatory system active in the biofilm. However, the complete stringent response regulon has not yet been mapped in *P. aeruginosa*, so this comparison could not be made.

Because the catabolite repression regulator (Crc) has been reported to modulate biofilm tolerance to ciprofloxacin (21), we tested for enrichment of Crc-regulated genes (74) in the biofilm transcriptome. No statistically significant overlap was found with the 340 genes upexpressed in biofilms (Table 6). Curiously, both

TABLE 7 Antibiotic susceptibility of selected *P. aeruginosa* mutants in biofilms

Strain/mutant	Locus	LR with CIP <sup>a</sup>	P <sup>b</sup>	LR with TOB <sup>a</sup>	P <sup>b</sup>	X <sub>0</sub> <sup>a,c</sup> (log <sub>10</sub> CFU cm <sup>-2</sup> )
MPAO1	WT <sup>d</sup>	0.9 ± 0.3		0.6 ± 0.2		9.8 ± 0.2
<i>anr</i> mutant	PA1544	2.6 ± 0.3	0.001	0.3 ± 0.4	0.52	8.8 ± 0.2
<i>rpoS</i> mutant	PA3622	2.9 ± 0.9	0.027	0.6 ± 0.3	0.96	10.1 ± 0.3
<i>relA spoT</i> mutant	PA0934, PA5338	2.4 ± 0.4	0.003	0.9 ± 0.4	0.30	9.9 ± 0.2
<i>mvfR</i> mutant	PA1003	1.2 ± 0.5	0.46	ND <sup>e</sup>		9.5 ± 0.4
<i>brlR</i> mutant	PA4878	ND		0.4 ± 0.4	0.54	9.8 ± 0.1
<i>lasI rhII</i> mutant	PA1432, PA3476	1.7 ± 0.4	0.07	0.5 ± 0.4	0.95	8.9 ± 0.2

<sup>a</sup> Uncertainty estimates are the standard deviations. LR, log reduction.

<sup>b</sup> P values are for the comparison to the log reduction measured for the wild type.

<sup>c</sup> X<sub>0</sub>, areal cell density of untreated biofilms.

<sup>d</sup> WT, wild type.

<sup>e</sup> ND, not determined.

genes that were negatively and positively regulated by Crc were enriched in the 683 genes downexpressed in biofilms (data not shown). Finally, we noticed a significant enrichment of genes positively regulated by MvfR (75) among the genes upexpressed in the biofilm (Table 6). A connection between MvfR and the downregulation of translational capacity, postulated to be involved in persister cell formation, was recently reported (76).

None of these regulatory genes themselves (*anr*, *rpoS*, *crc*, *relA*, *spoT*, or *mvfR*) were among the 340 upexpressed genes in the biofilm. In a similar *P. aeruginosa* biofilm experimental system, it was reported that the *rpoS* gene and RpoS protein were expressed in biofilm at levels comparable to those in stationary-phase planktonic cells (77).

In summary, in this biofilm system, global gene expression patterns are consistent with activation of the RpoS, MvfR, and Anr regulons but not the Crc regulon.

**Ciprofloxacin susceptibility of mutant strains grown as biofilms confirms a role for hypoxia and growth arrest stress responses in biofilm tolerance.** Based on the transcriptomics analysis, regulatory genes associated with oxygen limitation and growth arrest were hypothesized to contribute to biofilm antibiotic tolerance. We therefore tested the antibiotic susceptibility of strains with mutations that inactivated the global regulator involved in the hypoxia response, *anr*, and the stationary-phase sigma factor *rpoS*. The *anr*-E05::ISlacZ/hah and *rpoS*-B03::ISlacZ/hah mutant strains were obtained from the *P. aeruginosa* two-allele transposon mutant library (39) and were grown as biofilms (Table 7). Since both *anr* and *rpoS* are likely monocistronic, the transposon insertions are unlikely to be polar on downstream genes and affect only the expression of genes under their regulatory control. We also tested a stringent response-deficient double mutant,  $\Delta relA \Delta spoT$ , which was previously shown to be impaired in its ability to produce the stringent response signaling compound ppGpp (19). The *rpoS* and *relA spoT* mutants formed biofilms with cell densities similar to those of the wild type. The areal cell density of the *anr* mutant was an order of magnitude less than that of the wild-type strain. All three of these mutant strains were statistically significantly more susceptible to ciprofloxacin in the biofilm state. Whereas wild-type biofilms exhibited a 0.9-log reduction with ciprofloxacin challenge, the *anr*, *rpoS*, and *relA spoT* mutants yielded 2.4- to 2.9-log reductions. A quorum-sensing mutant (*lasI rhII*) deficient in the production of both acyl homoserine lactone synthases was borderline more susceptible to ciprofloxacin (Table 7).

Even though MvfR positively regulates 10% of the genes up-

expressed in biofilms, an *mvfR* mutant biofilm did not show increased susceptibility to ciprofloxacin (Table 7).


These results show that genes regulated by oxygen limitation, specifically via Anr, and by growth arrest, via both RpoS and the stringent response, contribute to biofilm tolerance to ciprofloxacin. This analysis does not identify the specific functional genes that participate in this effect, but it seems likely that multiple gene products are involved.

**Tobramycin susceptibility of mutant strains grown as biofilms failed to confirm any genetic basis for biofilm tolerance to tobramycin.** In contrast to the results with ciprofloxacin, the *anr*, *rpoS*, and *relA spoT* mutants yielded no differential susceptibility phenotype when grown as biofilms and challenged with tobramycin (Table 7), and neither did the double mutant deficient in acyl homoserine lactone quorum sensing.

The transcriptional regulator BrlR has been reported to govern antimicrobial susceptibility in *P. aeruginosa* biofilms (4, 20). Neither the *brlR* gene (PA4878) itself nor the drug efflux pump genes regulated by *brlR* were among the top 340 genes expressed more highly in drip-flow biofilms than in planktonic cells. Despite the lack of transcriptomic support for this mechanism, we tested the susceptibility of a *brlR* mutant grown as a biofilm to tobramycin (the antibiotic for which a biofilm phenotype was most extensively investigated in prior work). As with all other mutants examined, no reduced tobramycin tolerance was seen (Table 7). We note that our result does not contradict the findings of Liao and Sauer (4); at the identical dose concentration and duration, those researchers also reported an insignificant log reduction difference between the wild type and mutant. It was only at much higher tobramycin concentrations that these investigators discerned a phenotype.

In this work, we were not able to reproduce previously reported tobramycin biofilm susceptibility phenotypes for mutants affected in quorum sensing, stringent response, or the *brlR* gene. No mutant that we tested had a different susceptibility from that of the wild type when grown as a biofilm. One conclusion that could be made is that the particular set of genes that modulate antibiotic susceptibility in a biofilm may depend on parameters such as the strain, growth medium, biofilm age, and antibiotic dosing parameters. Another conclusion we can draw is that some other protective mechanism must be at work in a 3-day-old drip-flow biofilm challenged with tobramycin. Here, we propose an alternative explanation that has not yet been tested experimentally.

We hypothesize that many of the bacteria in 3-day-old drip-flow reactor biofilms have diminished membrane potential and that these cells are protected from tobramycin independent of



**FIG 1** Hypothesized physiological activities within mature *P. aeruginosa* drip-flow reactor biofilms. An oxenic zone (O) approximately 50  $\mu\text{m}$  thick overlies an anoxic zone (A) approximately 100  $\mu\text{m}$  thick. The shading denotes the oxygen concentration gradient, with darker shading indicating higher oxygen concentration and lighter shading indicating anaerobic conditions.

their genetic makeup or gene expression pattern. Tobramycin, like other aminoglycosides, is actively transported into the cytoplasm. This uptake is dependent on the cellular membrane potential (78). Bacterial cells in which the membrane potential is reduced will not take up tobramycin, and the drug will therefore not reach its intracellular target (78). This hypothesis is concordant with the evidence of oxygen starvation and arrested growth, both of which are plausible physiological preludes to diminished membrane potential. This hypothesis also predicts that genotype will be immaterial, as the pattern of gene expression in a cell is of no

significance if the antibiotic never enters the cell in the first place. If reduced membrane potential is responsible for tobramycin tolerance, it could be possible to enhance antibiotic efficacy by adding a substrate that restores the proton motive force and membrane potential (79, 80).

In this work, we tested only two antibiotics, and so we caution against extrapolating the results to other agents, particularly antibiotic classes other than fluoroquinolones or aminoglycosides.

**Role of physiological heterogeneity in biofilm antibiotic tolerance.** Most mature biofilms harbor considerable microscale physiological heterogeneity (81). We have described elsewhere the characterization of the significant chemical and biological heterogeneity in *P. aeruginosa* drip-flow biofilms (2, 82). These analyses included oxygen concentration gradients measured with microelectrodes (2), stratified protein synthetic activity revealed using an inducible green fluorescent protein (GFP) strain (2), and stratified mRNA content measured by laser microdissection, followed by either quantitative reverse transcription-PCR (44, 82) or microarray analysis (26). The hypothesized physiological activities and their spatial localization are diagrammed in Fig. 1. Transcription and translation are active in the oxenic zone, which constitutes the top one-third of the biofilm. Because of the steep oxygen concentration gradient in this region, bacteria in the oxenic zone express genetic responses to hypoxia and growth arrest, including those

**TABLE 8** Genes and proteins reported to be more highly expressed in *P. aeruginosa* biofilms than in planktonic cells in three or more experimental investigations

Locus ID <sup>a</sup>	Gene	T <sup>b</sup>	P <sup>c</sup>	Note <sup>d</sup>	Annotation
PA0139	<i>ahpC</i>	0	3	H <sub>2</sub> O <sub>2</sub>	Alkyl hydroperoxide reductase subunit C
PA0263	<i>hcpC</i>	1	2		Secreted protein Hcp
PA0515		3	0	O <sub>2</sub>	Probable transcriptional regulator
PA0588		2	2	O <sub>2</sub> , SP	Conserved hypothetical protein
PA0713		3	0	O <sub>2</sub> , SP	Hypothetical protein
PA1123		3	0	O <sub>2</sub> , SP	Hypothetical protein
PA1546	<i>hemN</i>	3	0	O <sub>2</sub> , SP	Oxygen-independent coproporphyrinogen III oxidase
PA1555	<i>ccoP2</i>	3	0	O <sub>2</sub> , SP	Cytochrome <i>c</i> oxidase, <i>ccb</i> <sub>3</sub> type, CcoP subunit
PA1556	<i>ccoO2</i>	3	0	O <sub>2</sub>	Cytochrome <i>c</i> oxidase, <i>ccb</i> <sub>3</sub> type, CcoO subunit
PA1673		3	0	O <sub>2</sub>	Hypothetical protein
PA1746		3	0	O <sub>2</sub> , SP	Hypothetical protein
PA1904	<i>phzF2</i>	3	0	PHZ, SP	Probable phenazine biosynthesis protein
PA1905	<i>phzG2</i>	2	1	PHZ, SP	Probable pyridoxamine 5'-phosphate oxidase
PA2274		3	0	O <sub>2</sub>	Hypothetical protein
PA2386	<i>pvdA</i>	0	3		L-Ornithine N <sup>5</sup> -oxygenase
PA2782		3	0		Hypothetical protein
PA3126	<i>ibpA</i>	3	1	O <sub>2</sub>	Heat shock protein IbpA
PA3309	<i>uspK</i>	2	2	O <sub>2</sub>	Usp-type stress protein essential for survival during pyruvate fermentation
PA3572		3	0	O <sub>2</sub> , SP	Hypothetical protein
PA4067	<i>oprG</i>	2	1	O <sub>2</sub>	Outer membrane protein OprG precursor
PA4211	<i>phzB1</i>	3	1	PHZ, SP	Probable phenazine biosynthesis protein
PA4217	<i>phzS</i>	2	1	PHZ	Flavin-containing monooxygenase
PA4236	<i>katA</i>	1	2	O <sub>2</sub> , H <sub>2</sub> O <sub>2</sub> , SP	Catalase
PA4352		3	2	O <sub>2</sub> , SP	Conserved hypothetical protein
PA4610		3	0	O <sub>2</sub>	Hypothetical protein
PA4765	<i>omlA</i>	2	1		Outer membrane lipoprotein OmlA precursor
PA5427	<i>adhA</i>	3	1	O <sub>2</sub> , SP	Alcohol dehydrogenase
PA5460		3	0		Hypothetical protein
PA5475		3	0	O <sub>2</sub> , SP	Hypothetical protein

<sup>a</sup> ID, identification.

<sup>b</sup> T, number of studies with transcriptomic identification.

<sup>c</sup> P, number of studies with proteomic identification.

<sup>d</sup> H<sub>2</sub>O<sub>2</sub>, peroxide stress; SP, stationary phase; O<sub>2</sub>, oxygen limitation; PHZ, phenazine biosynthesis.

mediated by *anr*, *rpoS*, and the stringent response. In a prior work, we showed strong expression of the ribosome hibernation factors *rmf* and PA4463 in this region (26). In the anoxic zone, which occupies the bottom two-thirds of the biofilm, anabolic activity, including transcription, is drastically reduced, and the cellular mRNA content is much lower than that in the oxic zone. Because they have such diminished amounts of mRNA, cells from the anoxic zone contribute little to the whole-biofilm transcriptome. Cells in the anoxic zone were at one time exposed to oxygen before being buried in the biofilm interior by continued cell growth. These cells therefore passed through the state of gene expression captured by the activity of cells in the oxic zone. The inactive cells in the anoxic zone may lose membrane potential over time and thereby evade killing by aminoglycosides. These cells may also be partially protected from killing by ciprofloxacin through the stress response genes that were expressed at an earlier time as the cells responded to oxygen limitation and a reduced growth rate.

What this model suggests is that the whole-biofilm transcriptome provides a snapshot of the gene expression occurring in the oxic zone of the biofilm. This snapshot is useful in that it suggests the direction in which these cells are headed, i.e., a dormant state for which they prepare by expressing overlapping stress responses, such as *anr*, *rpoS*, and the stringent response.

**Meta-analysis of genes and proteins expressed more highly in biofilm than in planktonic cells.** We compiled lists from six transcriptomic (2, 83–87) and five proteomic (88–92) investigations of differential expression between biofilm and planktonic cells. This expands on previous analyses (93–95). Across the 11 reports, 807 unique genes or proteins were reported to be more highly expressed in biofilms than in planktonic cells. There were 110 genes or proteins that were identified in two or more studies as being more highly expressed in biofilm and 29 genes or proteins identified in three or more of these studies (summarized in Table 8). When tested for overlap with the same set of gene lists named in Table 4, statistically significant enrichment was found for oxygen limitation ( $P = 10^{-13}$ ), oxygen downshift ( $P = 10^{-15}$ ), stationary phase ( $P = 10^{-10}$ ), and phenazine biosynthesis ( $P = 10^{-6}$ ). In contrast to our results with the drip-flow biofilms, no statistically significant evidence for homoserine lactone quorum sensing ( $P = 0.32$ ) or osmotic stress response ( $P = 1.00$ ) was detected. Six of the 11 papers reported genes expressed at lower levels in biofilm than in planktonic cells, with a total of 104 unique genes or proteins. No genes or proteins were identified that were more highly expressed in planktonic cells than in biofilms in three or more reports. Only three genes, PA1092 (*fliC*), PA4661 (*pagL*), and PA5348 (a probable DNA-binding protein), appeared on two lists. This meta-analysis supports the possibility that oxygen limitation and growth arrest are common physiological responses in *P. aeruginosa* biofilms and so may contribute to antibiotic tolerance, as described above.

## ACKNOWLEDGMENTS

This work was supported by NIH/NIAID award AII13330 and NIH/NIGMS award GM109452.

## REFERENCES

- Nickel JC, Wright JB, Ruseska I, Marris TJ, Whitfield C, Costerton JW. 1985. Antibiotic resistance of *Pseudomonas aeruginosa* colonizing a urinary catheter *in vitro*. *Eur J Clin Microbiol* 4:213–218. <http://dx.doi.org/10.1007/BF02013600>.
- Folsom JP, Richards L, Pitts B, Roe F, Ehrlich GD, Parker A, Mazurie A, Stewart PS. 2010. Physiology of *Pseudomonas aeruginosa* in biofilms as revealed by transcriptome analysis. *BMC Microbiol* 10:294. <http://dx.doi.org/10.1186/1471-2180-10-294>.
- Borriello G, Werner E, Roe F, Kim AM, Ehrlich GD, Stewart PS. 2004. Oxygen limitation contributes to antibiotic tolerance of *Pseudomonas aeruginosa* in biofilms. *Antimicrob Agents Chemother* 48:2659–2664. <http://dx.doi.org/10.1128/AAC.48.7.2659-2664.2004>.
- Liao J, Sauer K. 2012. The MerR-like transcriptional regulator BrIR contributes to *Pseudomonas aeruginosa* biofilm tolerance. *J Bacteriol* 194:4823–4836. <http://dx.doi.org/10.1128/JB.00765-12>.
- Stewart PS. 1996. Theoretical aspects of antibiotic diffusion into microbial biofilms. *Antimicrob Agents Chemother* 40:2517–2522.
- Stewart PS, Davison WM, Steenbergen JN. 2009. Daptomycin rapidly penetrates a *Staphylococcus epidermidis* biofilm. *Antimicrob Agents Chemother* 53:3505–3507. <http://dx.doi.org/10.1128/AAC.01728-08>.
- Suci PA, Mittelman MW, Yu FP, Geesey GG. 1994. Investigation of ciprofloxacin penetration into *Pseudomonas aeruginosa* biofilms. *Antimicrob Agents Chemother* 38:2125–2133. <http://dx.doi.org/10.1128/AAC.38.9.2125>.
- Shigeta M, Tanaka G, Komatsuzawa H, Sugai M, Suginata H, Usui T. 1997. Permeation of antimicrobial agents through *Pseudomonas aeruginosa* biofilms: a simple method. *Chemotherapy* 43:340–345. <http://dx.doi.org/10.1159/000239587>.
- Vrany JD, Stewart PS, Suci PA. 1997. Comparison of recalcitrance to ciprofloxacin and levofloxacin exhibited by *Pseudomonas aeruginosa* biofilms displaying rapid-transport characteristics. *Antimicrob Agents Chemother* 41:1352–1358.
- Walters MC, III, Roe F, Bugnicourt A, Franklin MJ, Stewart PS. 2003. Contributions of antibiotic penetration, oxygen limitation, and low metabolic activity to tolerance of *Pseudomonas aeruginosa* biofilms to ciprofloxacin and tobramycin. *Antimicrob Agents Chemother* 47:317–323. <http://dx.doi.org/10.1128/AAC.47.1.317-323.2003>.
- Tseng BS, Zhang W, Harrison JJ, Quach TP, Song JL, Penterman J, Singh PK, Chopp DL, Packman AI, Parsek MR. 2013. The extracellular matrix protects *Pseudomonas aeruginosa* biofilms by limiting the penetration of tobramycin. *Environ Microbiol* 15:2865–2878. <http://dx.doi.org/10.1111/1462-2920.12155>.
- Fridman O, Goldberg A, Ronin I, Shoshan N, Balaban NQ. 2014. Optimization of lag time underlies antibiotic tolerance in evolved bacterial populations. *Nature* 513:418–421. <http://dx.doi.org/10.1038/nature13469>.
- Macià MD, Pérez JL, Molin S, Oliver A. 2011. Dynamics of mutator and antibiotic-resistant populations in a pharmacokinetic/pharmacodynamic model of *Pseudomonas aeruginosa* biofilm treatment. *Antimicrob Agents Chemother* 55:5230–5237. <http://dx.doi.org/10.1128/AAC.00617-11>.
- Ciofu O, Mandsberg LF, Wang H, Høiby N. 2012. Phenotypes selected during chronic lung infection in cystic fibrosis patients: implications for the treatment of *Pseudomonas aeruginosa* biofilm infections. *FEMS Immunol Med Microbiol* 65:215–225. <http://dx.doi.org/10.1111/j.1574-695X.2012.00983.x>.
- Zhang L, Hinz AJ, Nadeau J-P, Mah T-F. 2011. *Pseudomonas aeruginosa* *tsxC1* links type VI secretion and biofilm-specific antibiotic resistance. *J Bacteriol* 193:5510–5513. <http://dx.doi.org/10.1128/JB.00268-11>.
- Mah T-FC, Pitts B, Pellock B, Walker GC, Stewart PS, O'Toole GA. 2003. A genetic basis for *Pseudomonas aeruginosa* biofilm antibiotic resistance. *Nature* 426:306–310. <http://dx.doi.org/10.1038/nature02122>.
- Zhang L, Mah T-F. 2008. Involvement of a novel efflux system in biofilm-specific resistance to antibiotics. *J Bacteriol* 190:4447–4452. <http://dx.doi.org/10.1128/JB.01655-07>.
- Colvin KM, Gordon VD, Murakami K, Borlee BR, Wozniak DJ, Wong GCL, Parsek MR. 2011. The Pel polysaccharide can serve a structural and protective role in the biofilm matrix of *Pseudomonas aeruginosa*. *PLoS Pathog* 7:e1001264. <http://dx.doi.org/10.1371/journal.ppat.1001264>.
- Nguyen D, Joshi-Datar A, Lepine F, Bauerle E, Olakanmi O, Beer K, McKay G, Siehnel R, Schafhauser J, Wang Y, Britigan BE, Singh PK. 2011. Active starvation responses mediate antibiotic tolerance in biofilms and nutrient-limited bacteria. *Science* 334:982–986. <http://dx.doi.org/10.1126/science.1211037>.
- Liao J, Schurr MJ, Sauer K. 2013. The MerR-like regulator BrIR confers biofilm tolerance by activating multidrug-efflux pumps in *Pseudomonas aeruginosa* biofilms. *J Bacteriol* 195:3352–3363. <http://dx.doi.org/10.1128/JB.00318-13>.
- Zhang L, Chiang W-C, Gao Q, Givskov M, Tolker-Nielsen T, Yang L, Zhang G. 2012. The catabolite repression control protein Crc plays a role in the development of antimicrobial-tolerant subpopulations in *Pseu-*

- domonas aeruginosa* biofilms. *Microbiology* 158(Pt 12):3014–3019. <http://dx.doi.org/10.1099/mic.0.061192-0>.
22. Anderl JN, Zahller J, Roe F, Stewart PS. 2003. Role of nutrient limitation and stationary-phase existence in *Klebsiella pneumoniae* biofilm resistance to ampicillin and ciprofloxacin. *Antimicrob Agents Chemother* 47:1251–1256. <http://dx.doi.org/10.1128/AAC.47.4.1251-1256.2003>.
  23. Werner E, Roe F, Bugnicourt A, Franklin MJ, Heydorn A, Molin S, Pitts B, Stewart PS. 2004. Stratified growth in *Pseudomonas aeruginosa* biofilms. *Appl Environ Microbiol* 70:6188–6196. <http://dx.doi.org/10.1128/AEM.70.10.6188-6196.2004>.
  24. Rani SA, Pitts B, Beyenal H, Veluchamy RA, Lewandowski Z, Davison WM, Buckingham-Meyer K, Stewart PS. 2007. Spatial patterns of DNA replication, protein synthesis, and oxygen concentration within bacterial biofilms reveal diverse physiological states. *J Bacteriol* 189:4223–4233. <http://dx.doi.org/10.1128/JB.00107-07>.
  25. Chávez de Paz LE, Hamilton IR, Svensäter G. 2008. Oral bacteria in biofilms exhibit slow reactivation from nutrient deprivation. *Microbiology* 154:1927–1938. <http://dx.doi.org/10.1099/mic.0.2008/016576-0>.
  26. Williamson KS, Richards LA, Perez-Osorio AC, Pitts B, McInerney K, Stewart PS, Franklin MJ. 2012. Heterogeneity in *Pseudomonas aeruginosa* biofilms includes expression of ribosome hibernation factors in the antibiotic-tolerant subpopulation and hypoxia-induced stress response in the metabolically active population. *J Bacteriol* 194:2062–2073. <http://dx.doi.org/10.1128/JB.00022-12>.
  27. Wentland E, Stewart PS, McFeters GA. 1996. Spatial variations in growth rate within *Klebsiella pneumoniae* colonies and biofilm. *Biotechnol Prog* 12:316–321. <http://dx.doi.org/10.1021/bp9600243>.
  28. Bernier SP, Lebeaux D, DeFrancesco AS, Valomon A, Soubigou G, Coppee J-Y, Ghigo JM, Beloin C. 2013. Starvation, together with the SOS response, mediates high biofilm-specific tolerance to the fluoroquinolone ofloxacin. *PLoS Genet* 9:e1003144. <http://dx.doi.org/10.1371/journal.pgen.1003144>.
  29. Lee S, Hinz A, Bauerle E, Angermeyer A, Juhaszova K, Kaneko Y, Singh PK, Manoil C. 2009. Targeting a bacterial stress response to enhance antibiotic action. *Proc Natl Acad Sci U S A* 106:14570–14575. <http://dx.doi.org/10.1073/pnas.0903619106>.
  30. Boles BR, Singh PK. 2008. Endogenous oxidative stress produces diversity and adaptability in biofilm communities. *Proc Natl Acad Sci U S A* 105:12503–12508. <http://dx.doi.org/10.1073/pnas.0801499105>.
  31. Jørgensen F, Bally M, Chapon-Herve V, Michel G, Lazdunski A, Williams P, Stewart GSAB. 1999. RpoS-dependent stress tolerance in *Pseudomonas aeruginosa*. *Microbiology* 145:835–844. <http://dx.doi.org/10.1099/13500872-145-4-835>.
  32. Dwyer DJ, Kohanski MA, Collins JJ. 2009. Role of reactive oxygen species in antibiotic action and resistance. *Curr Opin Microbiol* 12:482–489. <http://dx.doi.org/10.1016/j.mib.2009.06.018>.
  33. Kohanski MA, Dwyer DJ, Hayete B, Lawrence CA, Collins JJ. 2007. A common mechanism of cellular death induced by bactericidal antibiotics. *Cell* 130:797–810. <http://dx.doi.org/10.1016/j.cell.2007.06.049>.
  34. Pamp SJ, Gjermansen M, Johansen HK, Tolker-Nielsen T. 2008. Tolerance to the antimicrobial peptide colistin in *Pseudomonas aeruginosa* biofilms is linked to metabolically active cells, and depends on the *pmr* and *mexAB-oprM* genes. *Mol Microbiol* 68:223–240. <http://dx.doi.org/10.1111/j.1365-2958.2008.06152.x>.
  35. Wang X, Wood TK. 2011. Toxin-antitoxin systems influence biofilm and persist cell formation and the general stress response. *Appl Environ Microbiol* 77:5577–5583. <http://dx.doi.org/10.1128/AEM.05068-11>.
  36. Lewis K. 2007. Persister cells, dormancy and infectious disease. *Nat Rev Microbiol* 5:48–56. <http://dx.doi.org/10.1038/nrmicro1557>.
  37. Lewis K. 2008. Multidrug tolerance of biofilms and persister cells. *Curr Top Microbiol Immunol* 322:107–131. [http://dx.doi.org/10.1007/978-3-540-75418-3\\_6](http://dx.doi.org/10.1007/978-3-540-75418-3_6).
  38. Atlas RM. 1993. *Handbook of microbiological media*. CRC Press, Boca Raton, FL.
  39. Jacobs MA, Alwood A, Thaipisuttikul I, Spencer D, Haugen E, Ernst S, Will O, Kaul R, Raymond C, Levy R, Chun-Rong L, Guenther D, Bovee D, Olson MV, Manoil C. 2003. Comprehensive transposon mutant library of *Pseudomonas aeruginosa*. *Proc Natl Acad Sci U S A* 100:14339–14344. <http://dx.doi.org/10.1073/pnas.2036282100>.
  40. Hoang TT, Kutchma AJ, Becher A, Schweizer HP. 2000. Integration-proficient plasmids for *Pseudomonas aeruginosa*: site-specific integration and use for engineering of reporter and expression strains. *Plasmid* 43:59–72. <http://dx.doi.org/10.1006/plas.1999.1441>.
  41. Goeres DM, Hamilton MA, Beck NA, Buckingham-Meyer K, Hilyard JD, Loetterle LR, Lorenz LA, Walker DK, Stewart PS. 2009. A method for growing a biofilm under low shear at the air-liquid interface using the drip flow biofilm reactor. *Nat Protoc* 4:783–788. <http://dx.doi.org/10.1038/nprot.2009.59>.
  42. Barrett T, Edgar R. 2006. Gene Expression Omnibus: microarray data storage, submission, retrieval, and analysis. *Methods Enzymol* 411:352–369.
  43. Huang da W, Sherman BT, Lempicki RA. 2009. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. *Nat Protoc* 4:44–57. <http://dx.doi.org/10.1038/nprot.2008.211>.
  44. Huang da W, Sherman BT, Lempicki RA. 2009. Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. *Nucleic Acids Res* 37:1–13. <http://dx.doi.org/10.1093/nar/gkn923>.
  45. Pérez-Osorio AC, Williamson KS, Franklin MJ. 2010. Heterogeneous *rpoS* and *rhlR* mRNA levels and 16S rRNA/rDNA (rRNA gene) ratios within *Pseudomonas aeruginosa* biofilms, sampled by laser capture microdissection. *J Bacteriol* 192:2991–3000. <http://dx.doi.org/10.1128/JB.01598-09>.
  46. Keren I, Wu Y, Inocencio J, Mulcahy LR, Lewis K. 2013. Killing by bactericidal antibiotics does not depend on reactive oxygen species. *Science* 339:1213–1216. <http://dx.doi.org/10.1126/science.1232688>.
  47. Liu Y, Imlay JA. 2013. Cell death from antibiotics without the involvement of reactive oxygen species. *Science* 339:1210–1213. <http://dx.doi.org/10.1126/science.1232751>.
  48. Chang W, Small DA, Toghrol F, Bentley WE. 2005. Microarray analysis of *Pseudomonas aeruginosa* reveals induction of pyocin genes in response to hydrogen peroxide. *BMC Genomics* 6:115. <http://dx.doi.org/10.1186/1471-2164-6-115>.
  49. Hare NJ, Scott NE, Shin EHH, Connolly AM, Larsen MR, Palmisano G, Cordwell SJ. 2011. Proteomics of the oxidative stress response induced by hydrogen peroxide and paraquat reveals a novel AhpC-like protein in *Pseudomonas aeruginosa*. *Proteomics* 11:3056–3069. <http://dx.doi.org/10.1002/pmic.201000807>.
  50. Palma M, DeLuca D, Worgall S, Quadri LEN. 2004. Transcriptome analysis of the response of *Pseudomonas aeruginosa* to hydrogen peroxide. *J Bacteriol* 186:248–252. <http://dx.doi.org/10.1128/JB.186.1.248-252.2004>.
  51. Salunkhe P, Topfer T, Buer J, Tummeler B. 2005. Genome-wide transcriptional profiling of the steady-state response of *Pseudomonas aeruginosa* to hydrogen peroxide. *J Bacteriol* 187:2565–2572. <http://dx.doi.org/10.1128/JB.187.8.2565-2572.2005>.
  52. Cirz RT, O'Neill BM, Hammond JA, Head SR, Romesberg FE. 2006. Defining the *Pseudomonas aeruginosa* SOS response and its role in the global response to the antibiotic ciprofloxacin. *J Bacteriol* 188:7101–7110. <http://dx.doi.org/10.1128/JB.00807-06>.
  53. Winsor GL, Lam DK, Fleming L, Lo R, Whiteside MD, Yu NY, Hancock RE, Brinkman FS. 2011. *Pseudomonas* Genome Database: improved comparative analysis and population genomics capability for *Pseudomonas* genomes. *Nucleic Acids Res* 39(Database issue):D596–D600. <http://dx.doi.org/10.1093/nar/gkq869>.
  54. Ochsner UA, Wilderman PJ, Vasil AI, Vasil ML. 2002. GeneChip expression analysis of the iron starvation response in *Pseudomonas aeruginosa*: identification of novel pyoverdine biosynthetic genes. *Mol Microbiol* 45:1277–1287. <http://dx.doi.org/10.1046/j.1365-2958.2002.03084.x>.
  55. Palma MS, Worgall S, Quadri LE. 2003. Transcriptome analysis of the *Pseudomonas aeruginosa* response to iron. *Arch Microbiol* 180:374–379. <http://dx.doi.org/10.1007/s00203-003-0602-z>.
  56. Kulaskara H, Lee V, Brencic A, Liberati N, Urbach J, Miyata S, Lee DG, Neely AN, Hyodo M, Hayakawa Y, Ausubel FM, Lory S. 2006. Analysis of *Pseudomonas aeruginosa* diguanylate cyclases and phosphodiesterases reveals a role for bis-(3'-5')-cyclic-GMP in virulence. *Proc Natl Acad Sci U S A* 103:2839–2844. <http://dx.doi.org/10.1073/pnas.0511090103>.
  57. Pandey DP, Gerdes K. 2005. Toxin-antitoxin loci are highly abundant in free-living but lost from host-associated prokaryotes. *Nucleic Acids Res* 33:966–976. <http://dx.doi.org/10.1093/nar/gki201>.
  58. Breidenstein EBM, Khaira BK, Wiegand J, Overhage J, Hancock REW. 2008. Complex ciprofloxacin resistance revealed by screening a *Pseudomonas aeruginosa* mutant library for altered susceptibility. *Antimicrob Agents Chemother* 52:4486–4491. <http://dx.doi.org/10.1128/AAC.00222-08>.
  59. Gallagher LA, Shendure J, Manoil C. 2011. Genome-scale identification of resistance functions in *Pseudomonas aeruginosa* using Tn-seq. *mBio* 2:e00315-10. <http://dx.doi.org/10.1128/mBio.00315-10>.
  60. Brazas MD, Hancock REW. 2005. Ciprofloxacin induction of a susceptibility determinant. *Antimicrob Agents Chemother* 49:3222–3227. <http://dx.doi.org/10.1128/AAC.49.8.3222-3227.2005>.
  61. Kindrachuk KN, Fernández L, Bains M, Hancock RE. 2011. Involvement of

- an ATP-dependent protease, PA0779/AsrA, in inducing heat shock in response to tobramycin in *Pseudomonas aeruginosa*. *Antimicrob Agents Chemother* 55:1874–1882. <http://dx.doi.org/10.1128/AAC.00935-10>.
62. Alvarez-Ortega C, Harwood CS. 2007. Responses of *Pseudomonas aeruginosa* to low oxygen indicate that growth in the cystic fibrosis lung is by aerobic respiration. *Mol Microbiol* 65:153–165. <http://dx.doi.org/10.1111/j.1365-2958.2007.05772.x>.
  63. Trunk K, Benkert B, Quack N, Munch R, Scheer M, Garbe J, Jansch L, Trost M, Wehland J, Buer J, Jahn M, Schobert M, Jahn D. 2010. Anaerobic adaptation in *Pseudomonas aeruginosa*: definition of the Anr and Dnr regulons. *Environ Microbiol* 12:1719–1723. <http://dx.doi.org/10.1111/j.1462-2920.2010.02252.x>.
  64. Xu KD, Stewart PS, Xia F, Huang C-T, McFeters GA. 1998. Spatial physiological heterogeneity in *Pseudomonas aeruginosa* biofilm is determined by oxygen availability. *Appl Environ Microbiol* 64:4035–4039.
  65. Davies DG, Parsek MR, Pearson JP, Iglewski BH, Costerton JW, Greenberg EP. 1998. The involvement of cell-to-cell signals in the development of a bacterial biofilm. *Science* 280:295–298. <http://dx.doi.org/10.1126/science.280.5361.295>.
  66. De Kievit TR, Gillis R, Marx S, Brown C, Iglewski BH. 2001. Quorum-sensing genes in *Pseudomonas aeruginosa* biofilms: their role and expression patterns. *Appl Environ Microbiol* 67:1865–1873. <http://dx.doi.org/10.1128/AEM.67.4.1865-1873.2001>.
  67. Shrout JD, Chopp DL, Just CL, Hentzer M, Givskov M, Parsek MR. 2006. The impact of quorum sensing and swarming motility on *Pseudomonas aeruginosa* biofilm formation is nutritionally conditional. *Mol Microbiol* 62:1264–1277. <http://dx.doi.org/10.1111/j.1365-2958.2006.05421.x>.
  68. Bjarnsholt T, Jensen PØ, Burmølle M, Hentzer M, Haagensen JAJ, Hougen HP, Calum H, Madsen KG, Moser C, Molin S, Høiby N, Givskov M. 2005. *Pseudomonas aeruginosa* tolerance to tobramycin, hydrogen peroxide and polymorphonuclear leukocytes is quorum-sensing dependent. *Microbiology* 151:373–383. <http://dx.doi.org/10.1099/mic.0.27463-0>.
  69. Wagner VE, Bushnell D, Passador L, Brooks AI, Iglewski BH. 2003. Microarray analysis of *Pseudomonas aeruginosa* quorum-sensing regulons: effects of growth phase and environment. *J Bacteriol* 185:2080–2095. <http://dx.doi.org/10.1128/JB.185.7.2080-2095.2003>.
  70. Hentzer M, Wu H, Andersen JB, Riedel K, Rasmussen TB, Bagge N, Kumar N, Schembri MA, Song Z, Kristoffersen P, Manefield M, Costerton JW, Molin S, Eberl L, Steinberg P, Kjelleberg S, Høiby N, Givskov M. 2003. Attenuation of *Pseudomonas aeruginosa* virulence by quorum sensing inhibitors. *EMBO J* 22:3803–3815. <http://dx.doi.org/10.1093/emboj/cdg366>.
  71. Schuster M, Lostroh CP, Ogi T, Greenberg EP. 2003. Identification, timing, and signal specificity of *Pseudomonas aeruginosa* quorum-controlled genes: a transcriptome analysis. *J Bacteriol* 185:2066–2079. <http://dx.doi.org/10.1128/JB.185.7.2066-2079.2003>.
  72. Aspedon A, Palmer K, Whiteley M. 2006. Microarray analysis of osmotic stress response in *Pseudomonas aeruginosa*. *J Bacteriol* 188:2721–2725. <http://dx.doi.org/10.1128/JB.188.7.2721-2725.2006>.
  73. Schuster M, Hawkins AC, Harwood CS, Greenberg EP. 2004. The *Pseudomonas aeruginosa* RpoS regulon and its relationship to quorum sensing. *Mol Microbiol* 51:973–985. <http://dx.doi.org/10.1046/j.1365-2958.2003.03886.x>.
  74. Linares JF, Moreno R, Fajardo A, Martínez-Solano L, Escalante R, Rojo R, Martínez JL. 2010. The global regulator Crc modulates metabolism, susceptibility to antibiotics and virulence in *Pseudomonas aeruginosa*. *Environ Microbiol* 12:3196–3212. <http://dx.doi.org/10.1111/j.1462-2920.2010.02292.x>.
  75. Déziel E, Gopalan S, Tampakaki AP, Lépine F, Padfield KE, Saucier M, Xiao G, Rahme LG. 2005. The contribution of MvfR to *Pseudomonas aeruginosa* pathogenesis and quorum sensing circuitry regulation: multiple quorum sensing-regulated genes are modulated without affecting *lasRI*, *rhlRI* or the production of *N*-acyl-L-homoserine lactones. *Mol Microbiol* 55:998–1014. <http://dx.doi.org/10.1111/j.1365-2958.2004.04448.x>.
  76. Que Y-A, Hazan R, Strobel B, Maura D, He J, Kesarwani M, Panopoulos P, Tsurumi A, Giddey M, Wilhelmly J, Mindrinos MN, Rahme LG. 2013. A quorum sensing small volatile molecule promotes antibiotic tolerance in bacteria. *PLoS One* 8:e80140. <http://dx.doi.org/10.1371/journal.pone.0080140>.
  77. Xu KD, Franklin MJ, Park C-H, McFeters GA, Stewart PS. 2001. Gene expression and protein levels of the stationary phase sigma factor, RpoS, in continuously-fed *Pseudomonas aeruginosa* biofilms. *FEMS Microbiol Lett* 199:67–71. <http://dx.doi.org/10.1111/j.1574-6968.2001.tb10652.x>.
  78. Taber HW, Mueller JP, Miller PF, Arrow AS. 1987. Bacterial uptake of aminoglycoside antibiotics. *Microbiol Rev* 51:439–457.
  79. Allison KR, Brynildsen MP, Collins JJ. 2011. Metabolite-enabled eradication of bacterial persisters by aminoglycosides. *Nature* 473:216–220. <http://dx.doi.org/10.1038/nature10069>.
  80. Barraud N, Buson A, Jarolimek W, Rice SA. 2013. Mannitol enhances antibiotic sensitivity of persister bacteria in *Pseudomonas aeruginosa* biofilms. *PLoS One* 8:e84220. <http://dx.doi.org/10.1371/journal.pone.0084220>.
  81. Stewart PS, Franklin MJ. 2008. Physiological heterogeneity in biofilms. *Nat Rev Microbiol* 6:199–210. <http://dx.doi.org/10.1038/nrmicro1838>.
  82. Lenz AP, Williamson K, Pitts B, Stewart PS, Franklin MJ. 2008. Localized gene expression in *Pseudomonas aeruginosa* biofilms. *Appl Environ Microbiol* 74:4463–4471. <http://dx.doi.org/10.1128/AEM.00710-08>.
  83. Hentzer M, Eberl L, Givskov M. 2005. Transcriptome analysis of *Pseudomonas aeruginosa* biofilm development: anaerobic respiration and iron limitation. *Biofilms* 2:37–62. <http://dx.doi.org/10.1017/S14790505001699>.
  84. Mikkelsen H, Bond NJ, Skindersoe ME, Givskov M, Lilley KS, Welch M. 2009. Biofilms and type III secretion are not mutually exclusive in *Pseudomonas aeruginosa*. *Microbiology* 155:687–698. <http://dx.doi.org/10.1099/mic.0.025551-0>.
  85. Waite RD, Paccanaro A, Papakonstantinou A, Hurst JM, Saqi M, Littler E, Curtis MA. 2006. Clustering of *Pseudomonas aeruginosa* transcriptomes from planktonic cultures, developing and mature biofilms reveals distinct expression profiles. *BMC Microbiol* 7:162. <http://dx.doi.org/10.1186/1471-2164-7-162>.
  86. Whiteley M, Banger M, Bumgarner RE, Parsek MR, Teitzel GM, Lory S, Greenberg EP. 2001. Gene expression in *Pseudomonas aeruginosa* biofilms. *Nature* 413:860–864. <http://dx.doi.org/10.1038/35101627>.
  87. Bielecki P, Puchalka J, Wos-Oxley ML, Loessner H, Glik J, Kawecki M, Nowak M, Tummler B, Weiss S, Martins dos Santos VAP. 2011. *In-vivo* expression profiling of *Pseudomonas aeruginosa* infections reveals niche-specific and strain-independent transcriptional programs. *PLoS One* 6:e24235. <http://dx.doi.org/10.1371/journal.pone.0024235>.
  88. Mikkelsen H, Duck Z, Lilley KS, Welch M. 2007. Interrelationships between colonies, biofilms, and planktonic cells of *Pseudomonas aeruginosa*. *J Bacteriol* 189:2411–2416. <http://dx.doi.org/10.1128/JB.101687-06>.
  89. Sauer K, Camper AK, Ehrlich GD, Costerton JW, Davies DG. 2002. *Pseudomonas aeruginosa* displays multiple phenotypes during development as a biofilm. *J Bacteriol* 184:1140–1154. <http://dx.doi.org/10.1128/jb.184.4.1140-1154.2002>.
  90. Seyer D, Cosette P, Siroy A, De E, Lenz C, Vaudry H, Coquet L, Jouenne T. 2005. Proteomic comparison of outer membrane protein patterns of sessile and planktonic *Pseudomonas aeruginosa* cells. *Biofilms* 2:27–36. <http://dx.doi.org/10.1017/S14790505001638>.
  91. Southey-Pillig CJ, Davies DG, Sauer K. 2005. Characterization of temporal protein production in *Pseudomonas aeruginosa* biofilms. *J Bacteriol* 187:8114–8126. <http://dx.doi.org/10.1128/JB.187.23.8114-8126.2005>.
  92. Patrauchan MA, Sarkisova SA, Franklin MJ. 2007. Strain-specific proteome responses of *Pseudomonas aeruginosa* to biofilm-associated growth and to calcium. *Microbiology* 153:3838–3851. <http://dx.doi.org/10.1099/mic.0.2007/010371-0>.
  93. An D, Parsek MR. 2007. The promise and peril of transcriptional profiling in biofilm communities. *Curr Opin Microbiol* 10:292–296. <http://dx.doi.org/10.1016/j.mib.2007.05.011>.
  94. Lazazzera BA. 2005. Lessons from DNA microarray analysis: the gene expression profile of biofilms. *Curr Opin Microbiol* 8:222–227. <http://dx.doi.org/10.1016/j.mib.2005.02.015>.
  95. Patell S, Gu M, Davenport P, Givskov M, Waite RD, Welch M. 2010. Comparative microarray analysis reveals that the core biofilm-associated transcriptome of *Pseudomonas aeruginosa* comprises relatively few genes. *Environ Microbiol Rep* 2:440–448. <http://dx.doi.org/10.1111/j.1758-2229.2010.00158.x>.
  96. Lequette Y, Lee J-H, Ledgham F, Lazdunski A, Greenberg EP. 2006. A distinct QscR regulon in the *Pseudomonas aeruginosa* quorum-sensing circuit. *J Bacteriol* 188:3365–3370. <http://dx.doi.org/10.1128/JB.188.9.3365-3370.2006>.
  97. Nalca Y, Jansch L, Bredenbruch F, Geffers R, Buer J, Haussler S. 2006. Quorum-sensing antagonistic activities of azithromycin in *Pseudomonas aeruginosa* PAO1: a global approach. *Antimicrob Agents Chemother* 50:1680–1688. <http://dx.doi.org/10.1128/AAC.50.5.1680-1688.2006>.
  98. Teitzel GM, Geddie A, De Long SK, Kirisits MJ, Whiteley M, Parsek MR. 2006. Survival and growth in the presence of elevated copper: transcriptional profiling of copper-stressed *Pseudomonas aeruginosa*. *J Bacteriol* 188:7242–7256. <http://dx.doi.org/10.1128/JB.00837-06>.